SCHEMBL2846204

SCHEMBL2846204

O=C(O)N1CCc2c(nc(Nc3ccc(-c4cnco4)cc3)nc2OS(=O)(=O)C(F)(F)F)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 2/20 0.43
BRD4 O60885 1/20 0.43
TRPV1 Q8NER1 1/20 0.39
PRLHR P49683 5/20 0.37
SYK P43405 2/20 0.37
JAK3 P52333 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
IMPDH2 P12268 1/20 0.34
IMPDH1 P20839 1/20 0.34
PORCN Q9H237 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2452090 0.95 CREBBP (0.45) CREBBPBRD4TRPV1PRLHRSYK
SCHEMBL2842290 0.91 MAPT (0.44) CREBBPBRD4TRPV1PRLHRGPR119
SCHEMBL2449444 0.89 CREBBP (0.53) CREBBPBRD4TRPV1PRLHRCYP3A4
SCHEMBL2847251 0.86 MAPT (0.46) CREBBPBRD4TRPV1PRLHRGPR119
SCHEMBL2449701 0.83 CREBBP (0.49) CREBBPBRD4TRPV1SYKJAK3
SCHEMBL2844843 0.80 CREBBP (0.51) CREBBPBRD4TRPV1PRLHRSYK
SCHEMBL2558470 0.78 CREBBP (0.46) CREBBPBRD4
SCHEMBL2850690 0.77 CREBBP (0.45) CREBBPBRD4TRPV1SYKNPC1
SCHEMBL2846080 0.75 MAPT (0.49) CREBBPBRD4JAK3IMPDH2IMPDH1
SCHEMBL2449206 0.74 CREBBP (0.47) CREBBPBRD4TRPV1SYKNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 CREBBP 646/4885BRD4 1537/4885TRPV1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.